Small cell carcinoma of the prostate

An immunohistochemical study

Jorge L. Yao, Ralph Madeb, Patricia Bourne, Junyi Lei, Ximing Yang, Satish Tickoo, Zhengzhi Liu, Dongfeng Tan, Liang Cheng, Fadi Hatem, Jiaoti Huang, P. Anthony Di Sant'Agnese

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Small cell carcinoma of the prostate (SCPC) is morphologically similar to small cell carcinoma of the lung (SCLC) and maybe misinterpreted as Gleason pattern 5b prostate adenocarcinoma (HGPC). Recognition of SCPC is important because of its different clinical behavior. This study aims to characterize the immunophenotype of histologically classic SCPC using a comprehensive panel of markers, to better understand its histogenesis, aid in its classification, and evaluate potential therapeutic targets. Using the World Health Organization morphologic criteria for SCLC, 18 SCPC cases were identified; and studied for the following tumor marker groups: prostate specific/related, neuroendocrine, sex steroid hormone receptors, and prognostic/treatment target-related. Ten cases of UPC were used as controls. PSA was positive in 17% of SCPC and neuroendocrine markers were expressed in HGPC. PSA, TTF-1 and CD56 were the most helpful markers in differentiating between SCPC and HGPC (P<0.01), whereas bombesin/GRP, c-kit, bcl-2, and EGFR expression was more frequent in SCPC. SCPC is best diagnosed by following the World Health Organization diagnostic criteria for SCLC. Immunohistochemical markers can help separate SCPC from HGPC and may be useful in histologically borderline cases. Potential therapeutic targets are identified immunohistochemically in SCPC (Bombesin/GRP, c-kit, bcl-2, and EGFR).

Original languageEnglish
Pages (from-to)705-712
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume30
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Small Cell Carcinoma
Small Cell Lung Carcinoma
Prostate
Bombesin
Steroid Receptors
Gonadal Steroid Hormones
Tumor Biomarkers
Adenocarcinoma
Therapeutics

Keywords

  • Immunohistochemistry
  • Neuroendocrine
  • Prostate
  • Prostatic carcinoma
  • Small cell carcinoma
  • Therapeutic markers

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Yao, J. L., Madeb, R., Bourne, P., Lei, J., Yang, X., Tickoo, S., ... Anthony Di Sant'Agnese, P. (2006). Small cell carcinoma of the prostate: An immunohistochemical study. American Journal of Surgical Pathology, 30(6), 705-712. https://doi.org/10.1097/00000478-200606000-00005

Small cell carcinoma of the prostate : An immunohistochemical study. / Yao, Jorge L.; Madeb, Ralph; Bourne, Patricia; Lei, Junyi; Yang, Ximing; Tickoo, Satish; Liu, Zhengzhi; Tan, Dongfeng; Cheng, Liang; Hatem, Fadi; Huang, Jiaoti; Anthony Di Sant'Agnese, P.

In: American Journal of Surgical Pathology, Vol. 30, No. 6, 06.2006, p. 705-712.

Research output: Contribution to journalArticle

Yao, JL, Madeb, R, Bourne, P, Lei, J, Yang, X, Tickoo, S, Liu, Z, Tan, D, Cheng, L, Hatem, F, Huang, J & Anthony Di Sant'Agnese, P 2006, 'Small cell carcinoma of the prostate: An immunohistochemical study', American Journal of Surgical Pathology, vol. 30, no. 6, pp. 705-712. https://doi.org/10.1097/00000478-200606000-00005
Yao, Jorge L. ; Madeb, Ralph ; Bourne, Patricia ; Lei, Junyi ; Yang, Ximing ; Tickoo, Satish ; Liu, Zhengzhi ; Tan, Dongfeng ; Cheng, Liang ; Hatem, Fadi ; Huang, Jiaoti ; Anthony Di Sant'Agnese, P. / Small cell carcinoma of the prostate : An immunohistochemical study. In: American Journal of Surgical Pathology. 2006 ; Vol. 30, No. 6. pp. 705-712.
@article{8cb34b47ef5e42d99b1a6a534f150445,
title = "Small cell carcinoma of the prostate: An immunohistochemical study",
abstract = "Small cell carcinoma of the prostate (SCPC) is morphologically similar to small cell carcinoma of the lung (SCLC) and maybe misinterpreted as Gleason pattern 5b prostate adenocarcinoma (HGPC). Recognition of SCPC is important because of its different clinical behavior. This study aims to characterize the immunophenotype of histologically classic SCPC using a comprehensive panel of markers, to better understand its histogenesis, aid in its classification, and evaluate potential therapeutic targets. Using the World Health Organization morphologic criteria for SCLC, 18 SCPC cases were identified; and studied for the following tumor marker groups: prostate specific/related, neuroendocrine, sex steroid hormone receptors, and prognostic/treatment target-related. Ten cases of UPC were used as controls. PSA was positive in 17{\%} of SCPC and neuroendocrine markers were expressed in HGPC. PSA, TTF-1 and CD56 were the most helpful markers in differentiating between SCPC and HGPC (P<0.01), whereas bombesin/GRP, c-kit, bcl-2, and EGFR expression was more frequent in SCPC. SCPC is best diagnosed by following the World Health Organization diagnostic criteria for SCLC. Immunohistochemical markers can help separate SCPC from HGPC and may be useful in histologically borderline cases. Potential therapeutic targets are identified immunohistochemically in SCPC (Bombesin/GRP, c-kit, bcl-2, and EGFR).",
keywords = "Immunohistochemistry, Neuroendocrine, Prostate, Prostatic carcinoma, Small cell carcinoma, Therapeutic markers",
author = "Yao, {Jorge L.} and Ralph Madeb and Patricia Bourne and Junyi Lei and Ximing Yang and Satish Tickoo and Zhengzhi Liu and Dongfeng Tan and Liang Cheng and Fadi Hatem and Jiaoti Huang and {Anthony Di Sant'Agnese}, P.",
year = "2006",
month = "6",
doi = "10.1097/00000478-200606000-00005",
language = "English",
volume = "30",
pages = "705--712",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Small cell carcinoma of the prostate

T2 - An immunohistochemical study

AU - Yao, Jorge L.

AU - Madeb, Ralph

AU - Bourne, Patricia

AU - Lei, Junyi

AU - Yang, Ximing

AU - Tickoo, Satish

AU - Liu, Zhengzhi

AU - Tan, Dongfeng

AU - Cheng, Liang

AU - Hatem, Fadi

AU - Huang, Jiaoti

AU - Anthony Di Sant'Agnese, P.

PY - 2006/6

Y1 - 2006/6

N2 - Small cell carcinoma of the prostate (SCPC) is morphologically similar to small cell carcinoma of the lung (SCLC) and maybe misinterpreted as Gleason pattern 5b prostate adenocarcinoma (HGPC). Recognition of SCPC is important because of its different clinical behavior. This study aims to characterize the immunophenotype of histologically classic SCPC using a comprehensive panel of markers, to better understand its histogenesis, aid in its classification, and evaluate potential therapeutic targets. Using the World Health Organization morphologic criteria for SCLC, 18 SCPC cases were identified; and studied for the following tumor marker groups: prostate specific/related, neuroendocrine, sex steroid hormone receptors, and prognostic/treatment target-related. Ten cases of UPC were used as controls. PSA was positive in 17% of SCPC and neuroendocrine markers were expressed in HGPC. PSA, TTF-1 and CD56 were the most helpful markers in differentiating between SCPC and HGPC (P<0.01), whereas bombesin/GRP, c-kit, bcl-2, and EGFR expression was more frequent in SCPC. SCPC is best diagnosed by following the World Health Organization diagnostic criteria for SCLC. Immunohistochemical markers can help separate SCPC from HGPC and may be useful in histologically borderline cases. Potential therapeutic targets are identified immunohistochemically in SCPC (Bombesin/GRP, c-kit, bcl-2, and EGFR).

AB - Small cell carcinoma of the prostate (SCPC) is morphologically similar to small cell carcinoma of the lung (SCLC) and maybe misinterpreted as Gleason pattern 5b prostate adenocarcinoma (HGPC). Recognition of SCPC is important because of its different clinical behavior. This study aims to characterize the immunophenotype of histologically classic SCPC using a comprehensive panel of markers, to better understand its histogenesis, aid in its classification, and evaluate potential therapeutic targets. Using the World Health Organization morphologic criteria for SCLC, 18 SCPC cases were identified; and studied for the following tumor marker groups: prostate specific/related, neuroendocrine, sex steroid hormone receptors, and prognostic/treatment target-related. Ten cases of UPC were used as controls. PSA was positive in 17% of SCPC and neuroendocrine markers were expressed in HGPC. PSA, TTF-1 and CD56 were the most helpful markers in differentiating between SCPC and HGPC (P<0.01), whereas bombesin/GRP, c-kit, bcl-2, and EGFR expression was more frequent in SCPC. SCPC is best diagnosed by following the World Health Organization diagnostic criteria for SCLC. Immunohistochemical markers can help separate SCPC from HGPC and may be useful in histologically borderline cases. Potential therapeutic targets are identified immunohistochemically in SCPC (Bombesin/GRP, c-kit, bcl-2, and EGFR).

KW - Immunohistochemistry

KW - Neuroendocrine

KW - Prostate

KW - Prostatic carcinoma

KW - Small cell carcinoma

KW - Therapeutic markers

UR - http://www.scopus.com/inward/record.url?scp=33745890595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745890595&partnerID=8YFLogxK

U2 - 10.1097/00000478-200606000-00005

DO - 10.1097/00000478-200606000-00005

M3 - Article

VL - 30

SP - 705

EP - 712

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 6

ER -